

Charcot–Marie–Tooth disease: Genetics, epidemiology and complications

Masoumeh Pourhadi¹, Fereshteh Ahmadinejad¹, Reza Maghsoudi²,
 Mohammad-Saeid Jami^{1*}

¹Cellular and Molecular Research Center, Shahrekord University of Medical Sciences, Shahrekord, I.R. Iran; ²Microbiology Dept., Shahrekord University of Medical Sciences, Shahrekord, I.R. Iran.

Received: 12/Jun/2016 Accepted: 6/Nov/2016

ABSTRACT

Background and aims: Charcot Marie Tooth disease (CMT) is the most prevalent hereditary neuropathy and its frequency is 1 in 2500. CMT is a heterogeneous disease and has different clinical symptoms. The prevalence of CMT and involved genes differ in different countries. CMT patients experience considerable sleep problems and a higher risk of decreased quality of life. In this work it was aimed to provide a review on the genetic and epidemiologic aspects of this disease.

Methods: In the current review article, we performed a literature search on the epidemiology of Charcot–Marie–Tooth disease” and provided a brief review on epidemiology, genetic, and complications of CMT. Databases Web of Science and PubMed were searched using the Endnote software for the publications on CMT during 2000 to 2016.

Results: Charcot Marie Tooth disease has different prevalence around the world and is the most common neuropathy. Epidemiological studies have estimated the prevalence of CMT in Japan 1/9200, in Iceland 1/8300, in Spain 1/3500 and in Italy 1/5700. The patients have different phenotype and the age of onset. There is a variety of inherited patterns of disease and many genes have been identified responsible whose mutations are main cause of the disease.

Conclusion: Due to the impact of this kind of disabilities on the national health, further studies seem to be necessary to gain better knowledge of the disease particularly in the regions with higher prevalence. Moreover molecular biology services offered by genetic laboratories can reduce the incidence of disorder.

Keywords: Charcot Marie Tooth, Neuropathy, Electrophysiology, Epidemiology.

INTRODUCTION

The peroneal muscular atrophy was described about 120 years ago by Charcot, Marie and Tooth in Paris and England,

respectively. The described disorder was a familial and neurological disease. It was called CMT, to respect Charcot, Marie and

*Corresponding author: Mohammad-Saeid Jami, Cellular and Molecular Research Center, Shahrekord University of Medical Sciences, Shahrekord, I.R. Iran, Tel: 00989134138628, E-mail: sjamimail@yahoo.com

Tooth who described it for the first time. Charcot Marie Tooth disease (CMT) is the most prevalent hereditary neuropathy and its frequency is 1 in 2500. The other name of CMT disease is hereditary motor and sensory neuropathy(HMSN).^{1,2} Because of involving more than 80 genes in CMT, it is a heterogeneous group of inherited peripheral neuropathies.^{3,4} Based on electrophysiological index, CMT is subdivided into two major forms: demyelinating and axonal. In the demyelinating type, motor nerve conduction velocity (MNCV) is under 38 m/s whereas in axonal forms, MNCV is normal (above 38 m/s), but axons are affected. In the intermediate type of this disorder, intermediate MNCV about 25-45 m/s and/or heterogeneous clinical manifestation is common.⁵ The CMT disease has different inheritance pattern (including Autosomal Recessive(AR), Autosomal Dominant(AD), X-linked, and mitochondrial). In addition, the onset of CMT can be in different ages and clinical features varies in patients.⁶ Despite a high number of publications providing comprehensive and detailed information on CMT, there is little about the epidemiology of this disease. In this work, it was aimed to provide a concise review on the genetic and epidemiologic aspects of this disease. Databases Web of Science and PubMed were searched using the Endnote software for the publications on CMT during 2000 to 2016.

From the genetic perspective, Charcot Marie Tooth is a heterogeneous disease, but the clinical phenotype and manifestation is homogeneous and similar. This similar phenotype includes the weakness of distal limb muscles) especially the peroneal compartment of leg), loss of sensation in the distal extremities, skeletal abnormalities and reduction or lack of reflexes in deep tendons.⁷ Triad flaccid paresis, atrophy, and decreased or loss of reflexes are outcomes of the lower motor neuron damage. The severity of the disease ranges over a wide spectrum. Age of

onset is different among the patients, ranging from a floppy infant to an elderly man with slowly progressive peripheral neuropathy.⁸ The classic clinical picture of Charcot Marie Tooth disease is pes cavus, hammertoes, atrophy in muscles, weakness in the distal compartment of the legs, lack of vibratory sensation, absent of touch sensation and loss of reflexes in Achilles tendon.^{9,10}

The identification of inheritance pattern is the first step of CMT classification. CMT is inherited via autosomal dominant, autosomal recessive and X-linked patterns. The second step of classification is according to the process of neuropathy disorder in each subset.^{10,11} According to electrophysiological standards CMT is usually divided into two classes; demyelinating and axonal forms (CMT1 and CMT2 respectively). In CMT type 1 motor nerve conduction velocities (MNCV) is less than 38 m/s and the effect of demyelination and remyelination in nerves can be seen in sural nerve biopsy. In CMT type 2 motor nerve conduction velocities is somewhat decrease or even normal¹². CMT4 is Autosomal recessive and CMTX is not dependent to the Nerve Conduction Velocity.

To determine the subtypes in CMT disease, the mutant gene should be distinguished. It is known that more than 40 genes can cause CMT.¹³ Among CMT subtypes, duplication in PMP22 gene cause of the most common form of the disease, CMT1A. This subtype contains 70-80% of the CMT1 (demyelinating)cases.¹⁴ The subtype CMT2 manifested by MPZ mutations is involved in 10–30% of the CMT cases.¹⁵ Furthermore, GJB1 and GDAP1 mutations lead to CMTX1 and CMT4A respectively.

The clinical features are sometimes uncommon for CMT type 2, CMT type 4, and CMTX. For instance, CMT4 is recessive with early onset and severe symptoms.¹⁴ The cause of demyelinating form of CMT with Autosomal Dominant inheritance pattern (CMT type 1A) is usually PMP22

gene-duplication (on 17p11.2 locus) and it is almost 20% of all CMT cases with neuromuscular problems and a chronic peripheral neuropathy. Other causes for CMT1 (demyelinating) include mutations in P0 (1q22), LITAF (16p13) and EGR2 (10q21) genes.¹⁶ Table 1 and Table 2 summarize the main types of CMT together with the responsible gene and their chromosomal locus.

Table 1: The most common subtypes of CMT disease and the involved genes

CMT subtype	Mutation
CMT1A	PMP22 duplication
CMT2A2	MFN2
CMTX1	GJB1
CMT4A	GDAP1

Table 2: The chromosomal locus for the most prevalent types of CMT1

The mutant gene	Locus
PMP22	17p11.2
P0	1q22
LITAF	16p13
EGR2	10q21

Charcot Marie Tooth is a chronic disease and has an unpleasant effect on condition of patient's life. The undesirable effect impact different part of life, including mental and physical aspects.⁹

In CMT, disturbed sleep and respiratory system dysfunction may also be seen, which include the following items: obstructive apnea in sleep, streaked legs syndrome, vocal cord disorder, laryngeal neuron dysfunction and respiratory system impairment.¹⁷

In Germany, a large study was conducted on 200 patients with Charcot Marie Tooth¹³ wherein, patients complained

about fatigue, lack of good sleep and feeling sleepy during the day hours. Other symptoms including dysphagia, dyspnea and obstructive apnea in sleep was described in another report.¹⁸

Due to the lack of specific recommendations for the respiratory and sleep disorders, individuals need long-term care. Moreover, there are limitations for treatment of CMT patients during illness. Some reports show that during the pregnancy, patient's signs and symptoms become worse.¹⁹ In case of surgery, regional anesthesia is a good alternative to anesthetize rather than general anesthesia during pregnancy.¹⁹

CMT has been shown to increase the risk for complications during delivery, specifically abnormal birth presentation, post-partum bleed, and with higher rates of emergency interventions during delivery.²⁰ Many medications can cause patient's condition worse. For example, progesterone antagonists that are prescribed for treatment of CMT patients lead to abnormal baby born, dystocia and bleeding. Additionally, chemotherapy drugs like vinca alkaloids and taxol that target cell microtubules causing them depolymerized, lead to worsening CMT.²¹ It seems that these drugs cause disruption of axonal transportation and thus worsen or accelerate the development of new neuropathy. Chemotherapy drugs are not the only risk factors for the Charcot Marie Tooth disease, there is a large list of interventional medications prepared by the CMT Association which is regularly updated.²²

In all epidemiological studies, the important issue is whether the results can be generalize or not, and this depends on the population chosen for the study. In clinical trials, there is a non-partisan data collection, because the members elected in a clinical population and large families and patients with severe disabilities also participated in the study.²³ However, sporadic cases are

important because it shows disease with autosomal recessive inheritance pattern or a de-novo mutation. There are some items that can increase or decrease the estimation of disease prevalence. For example, misclassification of sporadic and familial non-CMT cases can increase the estimation and the CMT patients who do not participate in the study can reduce the estimation (eg, CMT2 has late onset and the person is a carrier of the disease but does not participate in the study).²⁴ Epidemiological studies have estimated the prevalence of CMT in Japan 1/9200, in Iceland 1/8300, in Spain 1/3500 and in Italy 1/5700. The difference in rates is mainly due to different methods used to determine and diagnose disease and sometimes because of human ethnicity and unequal distribution of point mutations in the world and dominance of founder effect in some areas. Clinical studies conducted that CMT1 outbreak is more than CMT2 and only one exception is in Japan, which founder effect occurred for MPZ gene (Thr124Met).²⁵ In a study conducted by G. J. Braathen in Akershus (the East Norway County), it was estimated that 13.6% of the families carry the PMP22 gene duplication while CX32 mutation was estimated to be about 6.2%. Moreover, MFN2 mutation and MPZ mutation were estimated around 6.2% and 4.8%, respectively.²⁶ The prevalence of duplication/deletion of PMP22 and MFN2 point mutation in the general population was less than clinical population, while for point mutation in CX32 the similar prevalence in both populations was estimated.^{14,27-29}

DISCUSSION

CMT is a heterogeneous disease and has different pattern of inheritance, different age of onset and different clinical symptoms. The outbreak and involved genes vary in different countries. Identifying common mutations in each region in the world can help to identify the involved

proteins and it is good for correct diagnosis of the disease and may be entered in the world of treatment. Unfortunately, epidemiological studies on CMT have not been yet conducted in Iran. Hopefully, the researches currently conducted by our group could identify affected individuals and families. This information together with our molecular genetic testing will further be of benefit to the patients and their families and will prevent from affected child birth.

CONCLUSION

Due to the impact of this kind of disabilities on the national health, further studies seem to be necessary to gain better knowledge of the disease particularly in the regions with higher prevalence. Moreover molecular biology services offered by genetic laboratories can reduce the incidence of disorder.

CONFLICT OF INTEREST

The authors declare that there are no conflicts of interest.

ACKNOWLEDGEMENT

We would like to thank all individuals who cooperated in this research and helped us to fill out the study.

REFERENCES

1. Hryshchenko NV, Livshits LA. Analysis of 17p11.2 chromosome region rearrangements in CMT1 patients from Ukraine. *Tsitol Genet.* 2009; 43(1): 36-41.
2. Ostern R, Fagerheim T, Hjellnes H, Nygard B, Mellgren SI, Nilssen O. Diagnostic laboratory testing for Charcot Marie Tooth disease (CMT): the spectrum of gene defects in Norwegian patients with CMT and its implications for future genetic test strategies. *BMC Med Genet.* 2013; 14: 94.

3. Bort S, Martinez F, Palau F. Prevalence and parental origin of de novo 1.5-Mb duplication in Charcot-Marie-Tooth disease type 1A. *Am J Hum Genet.* 1997; 60(1): 230-3.
4. Rudnik-Schoneborn S, Tolle D, Senderek J, Eggermann K, Elbracht M, Kornak U, et al. Diagnostic algorithms in Charcot-Marie-Tooth neuropathies: Experiences from a German genetic laboratory on the basis of 1206 index patients. *Clin Genet.* 2016; 89(1): 34-43.
5. Cartoni R, Martinou JC. Role of mitofusin 2 mutations in the physiopathology of Charcot-Marie-Tooth disease type 2A. *Exp Neurol.* 2009; 218(2): 268-73.
6. Gess B, Schirmacher A, Boentert M, Young P. Charcot-Marie-Tooth disease: frequency of genetic subtypes in a German neuromuscular center population. *Neuromuscul Disord.* 2013; 23(8): 647-51.
7. Pareyson D, Scaiola V, Laura M. Clinical and electrophysiological aspects of Charcot-Marie-Tooth disease. *Neuromolecular Med.* 2006; 8(1-2): 3-22.
8. Abe A, Numakura C, Kijima K, Hayashi M, Hashimoto T, Hayasaka K. Molecular diagnosis and clinical onset of Charcot-Marie-Tooth disease in Japan. *J Hum Genet.* 2011; 56(5): 364-8.
9. Cordeiro JL, Marques W, Hallak JE, Osorio FL. Charcot-Marie-Tooth disease, psychiatric indicators and quality of life: A systematic review. *ASN Neuro.* 2014; 6(3): 185-92.
10. Bouche P. [How to interpret the electromyogram (in neuromuscular diseases)]. *Rev Prat.* 1983; 33(11): 549-55.
11. Brust JC, Lovelace RE, Devi S. Clinical and electrodiagnostic features of Charcot-Marie-Tooth syndrome. *Acta Neurol Scand Suppl.* 1978; 68: 1-142.
12. De Jonghe P, Timmerman V, Nelis E, Martin JJ, Van Broeckhoven C. Charcot-Marie-Tooth disease and related peripheral neuropathies. *J Peripher Nerv Syst.* 1997; 2(4): 370-87.
13. Morocutti C, Colazza GB, Soldati G, D'Alessio C, Damiano M, Casali C, et al. Charcot-Marie-Tooth disease in Molise, a central-southern region of Italy: an epidemiological study. *Neuroepidemiology.* 2002; 21(5): 241-5.
14. Boerkoel CF, Takashima H, Garcia CA, Olney RK, Johnson J, Berry K, et al. Charcot-Marie-Tooth disease and related neuropathies: Mutation distribution and genotype-phenotype correlation. *Ann Neurol.* 2002; 51(2): 190-201.
15. Lawson VH, Graham BV, Flanigan KM. Clinical and electrophysiologic features of CMT2A with mutations in the mitofusin 2 gene. *Neurology.* 2005; 65(2): 197-204.
16. Dyck PJ. Hereditary motor and sensory neuropathies. *Neurology.* 1991; 41: 547-52.
17. Aboussouan LS, Lewis RA, Shy ME. Disorders of pulmonary function, sleep, and the upper airway in Charcot-Marie-Tooth disease. *Lung.* 2007; 185(1): 1-7.
18. McCorquodale D, Pucillo EM, Johnson NE. Management of Charcot-Marie-Tooth disease: Improving long-term care with a multidisciplinary approach. *J Multidiscip Healthc.* 2016; 9: 7-19.
19. Dematteis M, Pepin JL, Jeanmart M, Deschaux C, Labarre-Vila A, Levy P. Charcot-Marie-Tooth disease and sleep apnoea syndrome: A family study. *Lancet.* 2001; 357(9252): 267-72.
20. Benson B, Sulica L, Guss J, Blitzer A. Laryngeal neuropathy of Charcot-Marie-Tooth disease: Further observations and novel mutations associated with vocal fold paresis. *Laryngoscope.* 2010; 120(2): 291-6.
21. Boentert M, Knop K, Schuhmacher C, Gess B, Okegwo A, Young P. Sleep disorders in Charcot-Marie-Tooth disease type 1. *J Neurol Neurosurg Psychiatry.* 2014; 85(3): 319-25.
22. Brock M, Guinn C, Jones M. Anesthetic management of an obstetric patient with Charcot-Marie-Tooth disease: A case study. *AANA J.* 2009; 77(5): 335-7.

23. Berkson J. Limitations of the application of fourfold table analysis to hospital data. *Biometrics*. 1946; 2(3): 47-53.
24. Kurihara S, Adachi Y, Wada K, Awaki E, Harada H, Nakashima K. An epidemiological genetic study of Charcot-Marie-Tooth disease in Western Japan. *Neuroepidemiology*. 2002; 21(5): 246-50.
25. Combarros O, Calleja J, Polo JM, Berciano J. Prevalence of hereditary motor and sensory neuropathy in Cantabria. *Acta Neurol Scand*. 1987; 75(1): 9-12.
26. Bort S, Nelis E, Timmerman V, Sevilla T, Cruz-Martinez A, Martinez F, et al. Mutational analysis of the MPZ, PMP22 and Cx32 genes in patients of Spanish ancestry with Charcot-Marie-Tooth disease and hereditary neuropathy with liability to pressure palsies. *Hum Genet*. 1997; 99(6): 746-54.
27. Silander K, Meretoja P, Juvonen V, Ignatius J, Pihko H, Saarinen A, et al. Spectrum of mutations in Finnish patients with Charcot-Marie-Tooth disease and related neuropathies. *Hum Mutat*. 1998; 12(1): 59-68.
28. Lucotte G, Berriche S, Bathelier C, Turpin JC, Jacob P, Paquet JM, et al. Molecular characterization of Charcot-Marie-Tooth patients in 15 pedigrees from France. *Genet Couns*. 1995; 6(4): 355-60.
29. Braathen GJ. Genetic epidemiology of Charcot-Marie-Tooth disease. *Acta Neurol Scand Suppl*. 2012(193): iv-22.

How to cite the article: Pourhadi M, Ahmadinejad F, Maghsoudi R, Jami MS. Charcot-Marie-Tooth disease: Genetics, epidemiology and complications. *Int J Epidemiol Res*. 2017; 4(1): 78-83.